Societe Generale Downgrades ConocoPhillips to Sell, Raises Price Target to $114
Societe Generale analyst Raphael Dubois downgrades ConocoPhillips (NYSE:COP) from Hold to Sell and raises the price target from $106 to $114.
Keybanc Downgrades Federal Signal to Sector Weight
Keybanc analyst Steve Barger downgrades Federal Signal (NYSE:FSS) from Overweight to Sector Weight.
Gene Editing Stock’s Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Credit Suisse has downgraded Editas Medicine Inc (NASDAQ:EDIT) from Outperform to Neutral with a price target of $13 from $25. Thursday, Editas announced…
HP Analysts Go Cautious As Macro Concerns Challenge Near-Term Potential
Credit Suisse analyst Shannon Cross downgrades HP Inc (NYSE:HPQ) from Outperform to Neutral with a $33 price target. Cross believes revenue and…
BofA Is No Longer Bullish On Coinbase: ‘Fallout From FTX Clouds Outlook’
Coinbase Global Inc (NASDAQ: COIN) traded lower by 4.9% on Friday after the stock was hit by a Wall Street analyst downgrade.
Guggenheim Downgrades Surrozen to Neutral
Guggenheim analyst Yatin Suneja downgrades Surrozen (NASDAQ:SRZN) from Buy to Neutral.
Piper Sandler Downgrades Chart Industries to Neutral, Lowers Price Target to $133
Piper Sandler analyst Luke Lemoine downgrades Chart Industries (NYSE:GTLS) from Overweight to Neutral and lowers the price target from $228 to $133.
Oppenheimer Downgrades Editas Medicine to Perform, Lowers Price Target to $12
Oppenheimer analyst Jay Olson downgrades Editas Medicine (NASDAQ:EDIT) from Outperform to Perform and lowers the price target from $28 to $12.
Jefferies Downgrades SAP to Underperform
Jefferies analyst Charles Brennan downgrades SAP (NYSE:SAP) from Buy to Underperform.